| Ytd | 67.47% | |
| 1y | 426.80% |
| Open | 39.27 | Prev Close | 36.18 | Low | 37.77 | High | 40.19 | Mkt Cap | 1.96B |
| Vol | 111.77K | Avg Vol | 97.06K | EPS | -0.59 | P/E | -65.43 | Forward P/E | -112.79 |
| Beta | 0.57 | Short Ratio | 0.87 | Inst. Own | 11.75% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-31 | 50-d Avg | 37.68 | 200-d Avg | 30.17 | 1yr Est | 45.06 |
PARIS, July 30, 2026 (GLOBE NEWSWIRE) -- In accordance with articles L.233-8 II of the French Commer
Nanobiotix is rated a strong speculative Buy, driven by risk-adjusted upside from its JNJ-1900 radio
Nanobiotix is evolving into a capital-light, milestone- and royalty-driven oncology platform with JN
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regul
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: N
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: N
PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NB
PARIS and CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NB
PARIS, France and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NA
PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NB
PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NB
PARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NB
Nanobiotix wants to fundamentally change a century-old mainstay in battling cancer. The top-notch bi
Agilysys Inc (AGYS) shares rose in pre-market trading after reporting better-than-expected financial
Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTR
PARIS and CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:
Shares of Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report) have been given a consens
Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome commo
Nanobiotix (NASDAQ: NBTX - Get Free Report) and NRx Pharmaceuticals (NASDAQ: NRXP - Get Free Report)
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regul
Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report) shares gapped down prior to trading
U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of pu
U.S. stocks higher as Dow Jones gains 300 points; El Pollo LoCo Holdings jumps 17.6% on better-than-
U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday.
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced